## Review setup
- **Input scope** Abstract
- **Assessment boundary** Claims and evidence presented in the abstract only
- **Shared manuscript claim summary** The authors used CFD to optimize a transnasal aerosol delivery system for infants, achieving ~53.5% lung transmission, and derived design principles including hydrodynamic shielding, optimal interface geometry, and front-loading of aerosol emission.
- **Visible evidence base** Abstract text only; no figures, tables, or methods details provided
- **Missing materials affecting confidence** Full manuscript, figures, tables, validation data, CFD model details, in vitro experimental setup, statistical analysis

## Reviewer 1
- **Overall assessment** The abstract presents a potentially valuable computational optimization study for a clinically relevant problem (non-invasive surfactant delivery to preterm infants). The reported 53.5% lung transmission efficiency and the concept of "hydrodynamic shielding" are interesting. However, the abstract alone provides insufficient detail to evaluate the robustness of the CFD model, the validity of the in vitro validation, or the generalizability of the design principles. Several claims appear to be based on limited evidence or unspecified assumptions.
- **Who would be interested in the results, and why** Researchers and engineers in neonatal respiratory care, aerosol drug delivery, and medical device design. The study addresses a clear clinical need (non-invasive RDS treatment) and offers quantitative design guidelines that could inform future device development.
- **Major strengths** 1. Addresses a clinically important problem with a computational approach that can reduce costly experimental iterations. 2. Reports a specific, quantitative outcome (53.5% lung transmission) that sets a benchmark. 3. Identifies a novel concept ("hydrodynamic shielding") that may have broader applicability in aerosol delivery.
- **Major Concerns**
    - **Concern ID** R1-M1
    - **Severity** Major
    - **Blocking** Yes
    - **Axis** Validation and model fidelity
    - **Claim pointer** "The CFD model demonstrated strong in vitro agreement (2.8% mean absolute difference)."
    - **Evidence pointer** Abstract, location not provided
    - **Concern** The abstract states a 2.8% mean absolute difference between CFD and in vitro measurements, but provides no information on what quantity was compared (e.g., total lung dose, regional deposition, particle size distribution), under how many conditions, or with what variability. A single mean value is insufficient to establish model validity.
    - **Why it matters** Without knowing the scope and robustness of the validation, the entire optimization and the derived design principles rest on an unverified computational model. The 53.5% lung transmission claim is meaningless if the model is not adequately validated.
    - **Resolution test** The full manuscript must provide: (a) a clear description of the validation metric, (b) comparison across multiple conditions (e.g., different flow rates, particle sizes), (c) error bars or confidence intervals, and (d) a parity plot or similar visualization.
    - **Concern ID** R1-M2
    - **Severity** Major
    - **Blocking** Yes
    - **Axis** Generalizability and clinical relevance
    - **Claim pointer** "An optimal system-specific actuation flow rate of 3 L/min achieved ~53.5% aerosol lung transmission."
    - **Evidence pointer** Abstract, location not provided
    - **Concern** The abstract presents 53.5% as an optimal value, but it is unclear whether this is a single simulation result, an average of multiple runs, or the peak of a sensitivity analysis. The claim is presented as a definitive optimal value without any indication of the range of tested flow rates, the sensitivity of the result to flow rate, or the uncertainty in the prediction.
    - **Why it matters** A single optimal value without context is not actionable for device design. Clinicians and engineers need to know the robustness of this optimum and the trade-offs (e.g., does 2.5 L/min give 50%? Does 3.5 L/min give 45%?).
    - **Resolution test** The full manuscript must show a dose-response curve (lung transmission vs. flow rate) with error bars or confidence intervals, and discuss the sensitivity of the optimum to other parameters.
    - **Concern ID** R1-M3
    - **Severity** Major
    - **Blocking** Yes
    - **Axis** Completeness of evidence
    - **Claim pointer** "Integrating an upstream air volume created 'hydrodynamic shielding,' reducing relative interface losses by up to 50%."
    - **Evidence pointer** Abstract, location not provided
    - **Concern** The concept of "hydrodynamic shielding" is introduced without any mechanistic explanation or supporting data. The abstract does not specify the size of the upstream air volume, the geometry of the interface, or the baseline against which the 50% reduction is measured.
    - **Why it matters** This appears to be a key design principle, but the abstract provides no basis for understanding or reproducing it. The claim is currently unsupported.
    - **Resolution test** The full manuscript must provide: (a) a clear definition and mechanistic explanation of "hydrodynamic shielding," (b) a comparison of interface losses with and without the upstream volume, (c) the specific volume and geometry used, and (d) the range of conditions over which the 50% reduction was observed.
- **Minor Comments**
    - **Concern ID** R1-m1
    - **Severity** Minor
    - **Axis** Clarity
    - **Affected element** "20 degrees (inward and downward) prong alignment"
    - **Evidence pointer** Abstract, location not provided
    - **Issue** The description of the prong alignment is ambiguous. "Inward and downward" relative to what reference frame? Is this a single angle or two separate angles?
    - **Required correction** Clarify the coordinate system and specify whether this is a single compound angle or two independent angles.
    - **Concern ID** R1-m2
    - **Severity** Minor
    - **Axis** Terminology
    - **Affected element** "Front-loading of aerosol emission prevented entrapment of 10-14% of the dose in anatomical dead space."
    - **Evidence pointer** Abstract, location not provided
    - **Issue** The term "front-loading" is not defined. It is unclear whether this refers to a temporal concentration profile, a spatial distribution, or a specific actuation sequence.
    - **Required correction** Define "front-loading" explicitly (e.g., "emission of the majority of the aerosol dose within the first X% of the inhalation cycle").
    - **Concern ID** R1-m3
    - **Severity** Minor
    - **Axis** Readability
    - **Affected element** "balancing often competing aerosol generation physics, transport behavior, and clinical constraints"
    - **Evidence pointer** Abstract, location not provided
    - **Issue** This sentence is vague and does not specify which physics, transport behaviors, or clinical constraints are in competition.
    - **Required correction** Provide specific examples of the trade-offs (e.g., "balancing aerosolization efficiency against turbulence-driven transport losses" is already stated; expand to include other trade-offs).
- **Technical failings that need to be addressed before the case is established** R1-M1 (validation scope), R1-M2 (optimal value robustness), R1-M3 (hydrodynamic shielding evidence)
- **Assessment against Nature-style criteria** 
    - **Originality**: Moderate. The concept of "hydrodynamic shielding" may be novel, but the abstract does not provide enough detail to assess its novelty against existing literature on aerosol delivery optimization.
    - **Scientific importance**: High. Non-invasive surfactant delivery is a significant clinical need, and computational optimization can accelerate device development.
    - **Interdisciplinary readership**: Moderate. The topic is relevant to neonatology, aerosol science, and biomedical engineering, but the abstract is too technical for a general scientific audience.
    - **Technical soundness**: Not assessable from the abstract. The validation and optimization claims are unsupported.
    - **Readability for nonspecialists**: Poor. The abstract uses specialized terminology (e.g., "hydrodynamic shielding," "front-loading") without definition, and the clinical context is not sufficiently explained.
- **Recommendation posture** Currently not established from the provided evidence. The abstract presents interesting concepts and a promising result, but the key claims (validation, optimal efficiency, design principles) are unsupported. A full manuscript with detailed methods, validation data, and sensitivity analyses is required for a proper assessment.

## Risk / unsupported claims
1. "The CFD model demonstrated strong in vitro agreement (2.8% mean absolute difference)." – No scope, conditions, or variability provided.
2. "An optimal system-specific actuation flow rate of 3 L/min achieved ~53.5% aerosol lung transmission." – No sensitivity analysis, uncertainty, or range provided.
3. "Integrating an upstream air volume created 'hydrodynamic shielding,' reducing relative interface losses by up to 50%." – No mechanistic explanation, baseline, or supporting data.
4. "A 10 mm diffusive path length and 20 degrees (inward and downward) prong alignment balanced jet dissipation while minimizing nasal deposition." – No evidence that this is an optimum or that the trade-off was systematically explored.
5. "Front-loading of aerosol emission prevented entrapment of 10-14% of the dose in anatomical dead space." – No definition of "front-loading" or evidence for the 10-14% range.